Hopital europeen Georges Pompidou
Paris, 75015, France
NCT Number: NCT02165085
The purpose of this study is to determine whether patients with vascular Ehlers-Danlos syndrome present significant and specific changes of arterial endothelial and smooth muscular cell signalling/secretion, in comparison to matched healthy volunteers and patients with spontaneous arterial dissections.
Looking for future studies?
Notify Me18 year–70 year
All sexes
Observational
Paris, 75015, France
Vascular Ehlers-Danlos syndrome is a rare inherited disease which confers exceptional organ fragility in seamingly healthy young adults. The disease is caused by a mutation in the COL3A1 gene encoding type III collagen, critical to ensure physical resistance to mechanical stress of hollow organs. The disease results in increased tissular fragility, responsible of spontaneous arterial ruptures and dissections and spontaneous bowel perforations. The life-expectancy of patients with vascular Ehlers-Danlos syndrome is reduced by these recurring accidents. The exact mechanisms that trigger arterial accidents are unknown. Recent findings suggest a possible deleterious effect of inflammation and a possible dysregulation of the TGF-beta pathway. Thus, the purpose of this study is to identify further alterations in vascular endothelial and smooth muscular cell signalling/secretion, and to confirm previously suggested mechanisms of arterial accidents in vEDS patients.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
-All subjects must not present any chronic systemic disease, any acute disease within seven days prior to enrollment, diabetes mellitus and arterial hypertension.
Time frame: At the end of study (2 years after period of inclusion for first patient)
Analysis of the diagnostic value of different levels of plasma concentrations of microRNAs
Time frame: At the end of study (2 years after period of inclusion for first patient)
Compare patients with controls SEDv and two populations (patients with arterial accident spontaneous and healthy volunteers):microRNAs, the expression of circulating markers of tissue remodeling (plasma procollagen type I and III), the expression of a marker of inflammation (sensitivity C-reactive protein CRPus)
Assistance Publique - Hôpitaux de Paris
Other
Identification of Plasmatic Biomarkers in Vascular Ehlers-Danlos Syndrome
Acronym: MEDIC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05980104
Abnormalities, Multiple, Aneurysm
Palo Alto, California, United States
View Trial DetailsNCT07672210
Abnormalities, Multiple, Acute Aortic Syndrome
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT07516496
Aneurysm, Aortic Dissection
Cambridge, United Kingdom
View Trial DetailsNCT03440697
Abnormalities, Multiple, Acute Aortic Syndrome
Atlanta, Georgia, United States
View Trial Details